ArticleMetabolic engineering2019
Engineered mitochondrial production of monoterpenes in Saccharomyces cerevisiae.
Article in Metabolic engineering, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 152 citations in OpenAlex.
- Mitochondrial Targeting of MVA Pathway Triggers Severe Inhibition of Post-Squalene Cholesterol Biosynthesis: Transcriptomic and Proteomic Insights in Yeast.Molecules (Basel, Switzerland) · 2026Article
- Synthetic Biology of Plants and Microbes for Agriculture, Environment, and Future Applications.Chemical reviews · 2026Review
- Advances in mitochondrial compartmentalization for terpenoid synthesis inFrontiers in bioengineering and biotechnology · 2026Review
- Synthetic Biology in Natural Product Biosynthesis.Chemical reviews · 2025Review
- Harnessing organelle engineering to facilitate biofuels and biochemicals production in yeast.Journal of microbiology (Seoul, Korea) · 2025Review
- Shape Matters: The Utility and Analysis of Altered Yeast Mitochondrial Morphology in Health, Disease, and Biotechnology.International journal of molecular sciences · 2025Review
- Biotechnological production of terpenoids using cell factories.Frontiers in pharmacology · 2025Review
- Microbial biosynthesis of rare cannabinoids.Journal of industrial microbiology & biotechnology · 2024Article
- Synergistic increase in coproporphyrin III biosynthesis by mitochondrial compartmentalization in engineeredSynthetic and systems biotechnology · 2024Article
- Enhancing Substrate Preference of Iridoid Synthase via Focused Polarity-Steric Mutagenesis Scanning.Chem & bio engineering · 2024Article
- Efficient synthesis of limonene production in Yarrowia lipolytica by combinatorial engineering strategies.Biotechnology for biofuels and bioproducts · 2024Article
- De novo production of bioactive sesterterpenoid ophiobolins in Saccharomyces cerevisiae cell factories.Microbial cell factories · 2024Article
- Discovering a mitochondrion-localized BAHD acyltransferase involved in calystegine biosynthesis and engineering the production of 3β-tigloyloxytropane.Nature communications · 2024Article
- Biosynthesis Progress of High-Energy-Density Liquid Fuels Derived from Terpenes.Microorganisms · 2024Review
- Article
- Engineered biosynthesis of plant heteroyohimbine and corynantheine alkaloids in Saccharomyces cerevisiae.Journal of industrial microbiology & biotechnology · 2024Article
- EngineeringMetabolic engineering communications · 2023Article
- Article
- Review
- Metabolic Engineering of Model Microorganisms for the Production of Xanthophyll.Microorganisms · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Monoterpene indole alkaloids (MIAs) from plants encompass a broad class of structurally complex and medicinally valuable natural products. MIAs are biologically derived from the universal precursor strictosidine. Although the strictosidine biosynthetic pathway has been identified and reconstituted, extensive work is required to optimize production of strictosidine and its precursors in yeast. In this study, we engineered a fully integrated and plasmid-free yeast strain with enhanced production of the monoterpene precursor geraniol. The geraniol biosynthetic pathway was targeted to the mitochondria to protect the GPP pool from consumption by the cytosolic ergosterol pathway. The mitochondrial geraniol producer showed a 6-fold increase in geraniol production compared to cytosolic producing strains. We further engineered the monoterpene-producing strain to synthesize the next intermediates in the strictosidine pathway: 8-hydroxygeraniol and nepetalactol. Integration of geraniol hydroxylase (G8H) from Catharanthus roseus led to essentially quantitative conversion of geraniol to 8-hydroxygeraniol at a titer of 227 mg/L in a fed-batch fermentation. Further introduction of geraniol oxidoreductase (GOR) and iridoid synthase (ISY) from C. roseus and tuning of the relative expression levels resulted in the first de novo nepetalactol production. The strategies developed in this work can facilitate future strain engineering for yeast production of later intermediates in the strictosidine biosynthetic pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.